Literature DB >> 21453873

Visceral leishmaniasis: elimination with existing interventions.

Greg Matlashewski1, Byron Arana, Axel Kroeger, Sujit Battacharya, Shyam Sundar, Pradeep Das, Prabhat Kumar Sinha, Suman Rijal, Dinesh Mondal, Dan Zilberstein, Jorge Alvar.   

Abstract

The world's burden of infectious diseases can be substantially reduced by more-effective use of existing interventions. Advances in case detection, diagnosis, and treatment strategies have made it possible to consider the elimination of visceral leishmaniasis in the Indian subcontinent. The priority must now be to effectively implement existing interventions at the community level by actively finding cases in endemic villages and treating them with single-dose liposomal amphotericin B at primary-health-care centres. Once the elimination target of one case per 10,000 population has been reached, combination therapies involving miltefosine and paromomycin can be introduced to ensure long-term availability of several drugs for visceral leishmaniasis and to protect against resistance.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21453873     DOI: 10.1016/S1473-3099(10)70320-0

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  51 in total

1.  Identification of new antileishmanial leads from hits obtained by high-throughput screening.

Authors:  Xiaohua Zhu; Trupti Pandharkar; Karl Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.

Authors:  Susan Wyllie; Stephen Patterson; Laste Stojanovski; Frederick R C Simeons; Suzanne Norval; Robert Kime; Kevin D Read; Alan H Fairlamb
Journal:  Sci Transl Med       Date:  2012-02-01       Impact factor: 17.956

Review 3.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

Review 4.  Antimony transport mechanisms in resistant leishmania parasites.

Authors:  Frédéric Frézard; Rubens Monte-Neto; Priscila G Reis
Journal:  Biophys Rev       Date:  2014-01-25

5.  Evaluation of rK-39 strip test using urine for diagnosis of visceral leishmaniasis in an endemic region of India.

Authors:  Dharmendra Singh; Krishna Pandey; Vidya Nand Rabi Das; Sushmita Das; Neena Verma; Alok Ranjan; Sekhar Chandra Lal; Kamal Roshan Topno; Shubhankar Kumar Singh; Rakesh Bihari Verma; Ashish Kumar; Abul Hasan Sardar; Bidyut Purkait; Pradeep Das
Journal:  Am J Trop Med Hyg       Date:  2012-11-13       Impact factor: 2.345

6.  Repeated training of accredited social health activists (ASHAs) for improved detection of visceral leishmaniasis cases in Bihar, India.

Authors:  Vidya Nand Ravi Das; Ravindra Nath Pandey; Vijay Kumar; Krishna Pandey; Niyamat Ali Siddiqui; Rakesh Bihari Verma; Greg Matlashewski; Pradeep Das
Journal:  Pathog Glob Health       Date:  2016       Impact factor: 2.894

Review 7.  Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.

Authors:  Fabiana Alves; Graeme Bilbe; Séverine Blesson; Vishal Goyal; Séverine Monnerat; Charles Mowbray; Gina Muthoni Ouattara; Bernard Pécoul; Suman Rijal; Joelle Rode; Alexandra Solomos; Nathalie Strub-Wourgaft; Monique Wasunna; Susan Wells; Eduard E Zijlstra; Byron Arana; Jorge Alvar
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

Review 8.  Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence.

Authors:  Shyam Sundar; Om Prakash Singh; Jaya Chakravarty
Journal:  Expert Rev Anti Infect Ther       Date:  2018-10-10       Impact factor: 5.091

9.  Alkyl galactofuranosides strongly interact with Leishmania donovani membrane and provide antileishmanial activity.

Authors:  Muhammad Suleman; Jean-Pierre Gangneux; Laurent Legentil; Sorya Belaz; Yari Cabezas; Christelle Manuel; Rémy Dureau; Odile Sergent; Agnès Burel; Franck Daligault; Vincent Ferrières; Florence Robert-Gangneux
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

10.  Biomarkers for intracellular pathogens: establishing tools as vaccine and therapeutic endpoints for visceral leishmaniasis.

Authors:  A C Vallur; M S Duthie; C Reinhart; Y Tutterrow; S Hamano; K R H Bhaskar; R N Coler; D Mondal; S G Reed
Journal:  Clin Microbiol Infect       Date:  2013-11-18       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.